Vanguard Capital Management
ACXP icon

Vanguard Capital Management’s Acurx Pharmaceuticals ACXP Stock Holding History

Vanguard Capital Management’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.2K Hold
31,099
– – ﹤0.01% 3938
2026
Q1 		$115K Buy
+31,099
New +$88.2K ﹤0.01% 3853

Other funds holding ACXP

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
PFS
Prospect Financial Services Melville, New York $197M AUM 24.49% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Vanguard Capital Management's ACXP Position: Q2 2026 in Review

Vanguard Capital Management held its Acurx Pharmaceuticals (ACXP) position steady in Q2 2026 at 31,099 shares worth $48.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3938.

Vanguard Capital Management first reported a position in ACXP in Q1 2026 and has held it in 2 quarters since. The position peaked at $115K in Q1 2026. 19 funds tracked by Wall St. Rank hold ACXP as of Q2 2026.

  • Vanguard Capital Management held 31,099 shares of Acurx Pharmaceuticals worth $48.2K as of Q2 2026.
  • Vanguard Capital Management left its Acurx Pharmaceuticals share count unchanged in Q2 2026.
  • Acurx Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3938 holding.
  • Vanguard Capital Management first reported a position in Acurx Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Acurx Pharmaceuticals position peaked at $115K in Q1 2026.
  • 19 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.